Working... Menu
Trial record 1 of 1 for:    TG1101-RMS301 | Multiple Sclerosis
Previous Study | Return to List | Next Study

A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03277261
Recruitment Status : Active, not recruiting
First Posted : September 11, 2017
Last Update Posted : January 29, 2019
Information provided by (Responsible Party):
TG Therapeutics, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : March 31, 2021
  Estimated Study Completion Date : September 30, 2021